Remote ECG interpretation consultancy services for cardiovascular disease: Medtech innovation briefing [MIB152] – NICE

The technologies described in this briefing are remote electrocardiogram (ECG) interpretation consultancy services. They are used for assisting in diagnosing and decision-making for people with cardiovascular disease. The innovative aspects are that with remote ECG interpretation, a person does not need to travel

Mechanical thrombectomy devices for acute ischaemic stroke: Medtech innovation briefing [MIB153] – NICE

Thetechnologies described in this briefing are 21 mechanical thrombectomy devices of 2 types: stent retrievers and aspiration catheters. They are used to remove blood clots from a main cerebral artery to restore blood flow after acute ischaemic stroke. The innovative aspects are that

Low-intensity pulsed ultrasound to promote healing of fresh fractures at high risk of non-healing: Interventional procedures guidance [IPG622] – NICE

Evidence-based recommendations on low-intensity pulsed ultrasound to promote healing of fresh fractures at high risk of non-healing in adults. This involves using an ultrasound probe on the skin at the site of the fracture. The evidence for low-intensity pulsed ultrasound

Low-intensity pulsed ultrasound to promote healing of delayed-union and non-union fractures [IPG623] – NICE

Evidence-based recommendations on low-intensity pulsed ultrasound to promote healing of delayed-union and non-union fractures in adults. This involves using an ultrasound probe on the skin at the site of the fracture. The evidence for low-intensity pulsed ultrasound to promote healing

Low-intensity pulsed ultrasound to promote healing of fresh fractures at low risk of non-healing: Interventional procedures guidance [IPG621] – NICE

Evidence-based recommendations on low-intensity pulsed ultrasound to promote healing of fresh fractures at low risk of non-healing in adults. This involves using an ultrasound probe on the skin at the site of the fracture. The evidence for low-intensity pulsed ultrasound

Dupilumab for treating moderate to severe atopic dermatitis: Technology appraisal guidance [TA534] – NICE

Evidence-based recommendations on dupilumab (Dupixent) for treating moderate to severe atopic dermatitis in adults. Dupilumab is recommended as an option for treating moderate to severe atopic dermatitis in adults, only if: the disease has not responded to at least 1 other

Ixekizumab for treating active psoriatic arthritis after inadequate response to DMARDs: Technology appraisal guidance [TA537] – NICE

Evidence-based recommendations on ixekizumab (Taltz) for treating active psoriatic arthritis in adults. Ixekizumab alone, or with methotrexate, is recommended as an option for treating active psoriatic arthritis in adults, only if: it is used as described in NICE’s technology appraisal

Lenvatinib and sorafenib for treating differentiated thyroid cancer after radioactive iodine: Technology appraisal guidance [TA535] – NICE

Evidence-based recommendations on lenvatinib (Lenvima) and sorafenib (Nexavar) for progressive, locally advanced or metastatic differentiated thyroid cancer in adults who have had radioactive iodine. Lenvatinib and sorafenib are recommended as options for treating progressive, locally advanced or metastatic differentiated thyroid

Pembrolizumab for untreated PD-L1-positive metastatic non-small-cell lung cancer: Technology appraisal guidance [TA531] – NICE

Evidence-based recommendations on pembrolizumab (Keytruda) for untreated PD-L1-positive metastatic non-small-cell lung cancer in adults. This guidance replaces NICE technology appraisal guidance 447.

Airglove air warming system for venous access: Medtech innovation briefing [MIB151] – NICE

The technology described in this briefing is Airglove. It is used to warm and raise the veins in the arm to help with cannula insertion. The innovative aspects are claimed to be that there are no other devices available which warm the

Biomarker tests to help diagnose preterm labour in women with intact membranes: Diagnostics guidance [DG33] – NICE

Evidence-based recommendations on biomarker tests to help diagnose preterm labour in women with intact membranes. The tests are Actim Partus, PartoSure and the Rapid fetal fibronectin (fFN) 10Q Cassette Kit (at thresholds other than 50 nanograms/millilitre).

Guselkumab for treating moderate to severe plaque psoriasis: Technology appraisal guidance [TA521] – NICE

Evidence-based recommendations on guselkumab (Tremfya) for treating moderate to severe plaque psoriasis in adults. Guselkumab is recommended as an option for treating plaque psoriasis in adults, only if: the disease is severe, as defined by a total Psoriasis Area and Severity

ORA G3 to measure corneal hysteresis: Medtech innovation briefing [MIB150] – NICE

NICE has developed a medtech innovation briefing (MIB) on ORA G3 to measure corneal hysteresis a possible risk factor for glaucoma. Key uncertainties around the evidence or technology are whether the published studies are applicable to the NHS, and if

Laparoscopic ventral mesh rectopexy for internal rectal prolapse: Interventional procedures guidance [IPG618] – NICE

Evidence-based recommendations on laparoscopic ventral mesh rectopexy for internal rectal prolapse in adults. This involves using a piece of sterile material (mesh) to attach the rectum to the lower back bone using keyhole surgery. Current evidence on the safety of

Unilateral MRI-guided focused ultrasound thalamotomy for treatment-resistant essential tremor: Interventional procedures guidance [IPG617] – NICE

Evidence-based recommendations on unilateral MRI-guided focused ultrasound thalamotomy for treatment-resistant essential tremor in adults. This involves applying ultrasound to a specific area on 1 side of the brain (thalamus). The evidence on the safety of unilateral MRI-guided focused ultrasound thalamotomy for

Intranasal phototherapy for allergic rhinitis: Interventional procedures guidance [IPG616] – NICE

Evidence-based recommendations on intranasal phototherapy for allergic rhinitis in adults. This involves using light to reduce inflammation inside the nose. Current evidence on the efficacy and safety of intranasal phototherapy for allergic rhinitis is limited in quantity and quality. Therefore,

Donepezil, galantamine, rivastigmine and memantine for the treatment of Alzheimer’s disease: Technology appraisal guidance [TA217] – NICE

Evidence-based recommendations on donepezil (Aricept), galantamine (Reminyl), rivastigmine (Exelon) and memantine (Ebixa) for treating Alzheimer’s disease in adults. This guidance has been partially updated by NICE’s guideline on dementia (NG97) and replaces NICE technology appraisal guidance on donepezil, galantamine, rivastigmine

Beta interferons and glatiramer acetate for treating multiple sclerosis: Technology appraisal guidance [TA527] – NICE

Evidence-based recommendations on beta interferons (Avonex, Betaferon, Extavia, Rebif) and glatiramer acetate (Copaxone) for treating multiple sclerosis in adults. This guidance replaces NICE technology appraisal guidance 32 on beta interferon and glatiramer acetate for the treatment of multiple sclerosis.

Pembrolizumab for untreated locally advanced or metastatic urothelial cancer when cisplatin is unsuitable: Technology appraisal guidance [TA522] – NICE

Evidence-based recommendations on pembrolizumab (Keytruda) for untreated locally advanced or metastatic urothelial carcinoma in adults.

Midostaurin for untreated acute myeloid leukaemia: Technology appraisal guidance [TA523] – NICE

Evidence-based recommendations on midostaurin (Rydapt) for untreated FLT3-mutation-positive acute myeloid leukaemia in adults.